Literature DB >> 817693

Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain.

A S Dekaban, G Constantopoulos, M M Herman, J K Steusing.   

Abstract

Multidisciplinary studies were conducted on the brain and other tissues of patients who died with the antemortem diagnosis of mucopolysaccharidosis (MPS) of one of the following types; type V, Scheie disease (MPS-V); type I, Hurler disease (MPS-I): and type II, Hunter disease (MPS-II). The principal new finding in the brain of the patient with MPS-V is the presence of lesions in the periadventitial mesenchymal tissue of the white matter, similar to those of MPS-I, while the nerve cells in MPS-V are histologically normal, in contradistinction to MPS-I, in which the neuronal abnormality is severe. Electron microscopical studies of the brain in MPS-I demonstrated numerous complex membranous inclusions in the neurons, whereas the neurons in MPS-V contained only a small number of lipofuscin-like inclusions and typical lipofuscin granules. There was a threefold increase of glycosaminoglycans (GAG) in the brain of MPS-I, but only a slight increase in the MPS-V; GAG in the liver and spleen of all patients was noticeably increased. alpha-L-iduronidase activity was not detectable in the brain and liver of patients with MPS-I and MPS-V, thus suggesting a similar enzymatic defect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 817693

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

2.  Neuropathological and clinical correlations in Hurler disease.

Authors:  R W Watts; E Spellacy; J H Adams
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I.

Authors:  Haruhito Harada; Hiroshi Niiyama; Atsushi Katoh; Hisao Ikeda
Journal:  JIMD Rep       Date:  2014-05-22

4.  Computed tomography studies on patients with mucopolysaccharidoses.

Authors:  R W Watts; E Spellacy; B E Kendall; G du Boulay; D A Gibbs
Journal:  Neuroradiology       Date:  1981-02       Impact factor: 2.804

5.  Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells.

Authors:  Chendong Pan; Matthew S Nelson; Morayma Reyes; Lisa Koodie; Joseph J Brazil; Elliot J Stephenson; Robert C Zhao; Charles Peters; Scott B Selleck; Sally E Stringer; Pankaj Gupta
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

6.  Two cases of mucopolysaccharidosis type III (Sanfilippo). An anatomopathological study.

Authors:  J J Martin; C Ceuterick; G Van Dessel; A Lagrou; W Dierick
Journal:  Acta Neuropathol       Date:  1979-05-15       Impact factor: 17.088

7.  Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain.

Authors:  A S Dekaban; G Constantopoulos
Journal:  Acta Neuropathol       Date:  1977-07-15       Impact factor: 17.088

8.  Biochemical and histopathological studies on patients with mucopolysaccharidoses, two of whom had been treated by fibroblast transplantation.

Authors:  J Crow; D A Gibbs; W Cozens; E Spellacy; R W Watts
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

9.  The pathology of the feline model of mucopolysaccharidosis I.

Authors:  M E Haskins; G D Aguirre; P F Jezyk; R J Desnick; D F Patterson
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.